You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameForasartan
Accession NumberDB01342
TypeSmall Molecule
GroupsApproved
DescriptionForasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Structure
Thumb
Synonyms
Forasartan
SC-52458
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII065F7WPT0B
CAS number145216-43-9
WeightAverage: 416.522
Monoisotopic: 416.243692936
Chemical FormulaC23H28N8
InChI KeyInChIKey=YONOBYIBNBCDSJ-UHFFFAOYSA-N
InChI
InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30)
IUPAC Name
5-[(dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]pyridine
SMILES
CCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPhenylpyridines
Direct ParentPhenylpyridines
Alternative Parents
Substituents
  • 2-phenylpyridine
  • Phenyltetrazole
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Tetrazole
  • Azole
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension.
PharmacodynamicsForasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. By inhibiting angiotensin II receptors, this drug leads to a decrease in sodium reabsorption (which decreases water content of blood) and a decrease in vasoconstriction. Combined, this has the effect of lowering blood pressure.
Mechanism of actionForasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. Also, since angiotensin causes vasoconstriction, the inhibition of this receptor decreases vasoconstriction, which consequently also decreases vascular resistnace.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Forasartan Action PathwayDrug actionSMP00160
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9069
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.615
P-glycoprotein inhibitor INon-inhibitor0.6612
P-glycoprotein inhibitor IINon-inhibitor0.8805
Renal organic cation transporterInhibitor0.5228
CYP450 2C9 substrateNon-substrate0.7854
CYP450 2D6 substrateNon-substrate0.831
CYP450 3A4 substrateNon-substrate0.5512
CYP450 1A2 substrateNon-inhibitor0.64
CYP450 2C9 inhibitorNon-inhibitor0.5115
CYP450 2D6 inhibitorNon-inhibitor0.7168
CYP450 2C19 inhibitorInhibitor0.7661
CYP450 3A4 inhibitorInhibitor0.6576
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7192
Ames testNon AMES toxic0.5233
CarcinogenicityNon-carcinogens0.8243
BiodegradationNot ready biodegradable0.9969
Rat acute toxicity2.7970 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6462
hERG inhibition (predictor II)Non-inhibitor0.546
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00667 mg/mLALOGPS
logP4.51ALOGPS
logP5.89ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)7.35ChemAxon
pKa (Strongest Basic)3.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area98.06 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity145.44 m3·mol-1ChemAxon
Polarizability46.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AceclofenacThe risk or severity of adverse effects can be increased when Forasartan is combined with Aceclofenac.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Forasartan is combined with Adapalene.
AliskirenAliskiren may increase the hyperkalemic activities of Forasartan.
AmilorideForasartan may increase the hyperkalemic activities of Amiloride.
AntipyrineThe risk or severity of adverse effects can be increased when Forasartan is combined with Antipyrine.
ApremilastThe risk or severity of adverse effects can be increased when Forasartan is combined with Apremilast.
ArdeparinArdeparin may increase the hyperkalemic activities of Forasartan.
AzapropazoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Forasartan is combined with Azelastine.
BalsalazideThe risk or severity of adverse effects can be increased when Forasartan is combined with Balsalazide.
BemiparinBemiparin may increase the hyperkalemic activities of Forasartan.
BenazeprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Benazepril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Benoxaprofen.
BromfenacThe risk or severity of adverse effects can be increased when Forasartan is combined with Bromfenac.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Forasartan.
CandoxatrilThe risk or severity of adverse effects can be increased when Forasartan is combined with Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Captopril.
CarprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Carprofen.
CastanospermineThe risk or severity of adverse effects can be increased when Forasartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Celecoxib.
CertoparinCertoparin may increase the hyperkalemic activities of Forasartan.
ChloroquineThe risk or severity of adverse effects can be increased when Forasartan is combined with Chloroquine.
CilazaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Cilazapril.
CiprofloxacinForasartan may increase the arrhythmogenic activities of Ciprofloxacin.
ClonixinThe risk or severity of adverse effects can be increased when Forasartan is combined with Clonixin.
CyclosporineForasartan may increase the hyperkalemic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Forasartan is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Forasartan.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Forasartan.
DiclofenacThe risk or severity of adverse effects can be increased when Forasartan is combined with Diclofenac.
DiflunisalThe risk or severity of adverse effects can be increased when Forasartan is combined with Diflunisal.
DrospirenoneForasartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Droxicam.
EnalaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Enalapril.
EnalaprilatThe risk or severity of adverse effects can be increased when Forasartan is combined with Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Forasartan.
EpirizoleThe risk or severity of adverse effects can be increased when Forasartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Forasartan.
EtanerceptThe risk or severity of adverse effects can be increased when Forasartan is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Forasartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Forasartan is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Forasartan is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Forasartan is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Forasartan is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Forasartan is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Forasartan is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Flurbiprofen.
FosinoprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Fosinopril.
HeparinHeparin may increase the hyperkalemic activities of Forasartan.
HMPL-004The risk or severity of adverse effects can be increased when Forasartan is combined with HMPL-004.
IbuprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Forasartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Forasartan is combined with Icatibant.
IndomethacinThe risk or severity of adverse effects can be increased when Forasartan is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Indoprofen.
IsoxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Isoxicam.
KebuzoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Forasartan is combined with Ketorolac.
LeflunomideThe risk or severity of adverse effects can be increased when Forasartan is combined with Leflunomide.
LisinoprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Forasartan.
LornoxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Lornoxicam.
LoxoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Forasartan is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Forasartan is combined with Masoprocol.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Forasartan is combined with Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Forasartan is combined with Metamizole.
MoexiprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Moexipril.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Nabumetone.
NadroparinNadroparin may increase the hyperkalemic activities of Forasartan.
NaftifineThe risk or severity of adverse effects can be increased when Forasartan is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Forasartan is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Forasartan is combined with NCX 4016.
NepafenacThe risk or severity of adverse effects can be increased when Forasartan is combined with Nepafenac.
NicorandilNicorandil may increase the hyperkalemic activities of Forasartan.
Niflumic AcidThe risk or severity of adverse effects can be increased when Forasartan is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Forasartan is combined with Nimesulide.
OlopatadineThe risk or severity of adverse effects can be increased when Forasartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Forasartan is combined with Olsalazine.
OmapatrilatThe risk or severity of adverse effects can be increased when Forasartan is combined with Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Forasartan is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxaprozin.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxyphenbutazone.
ParecoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Parecoxib.
ParnaparinParnaparin may increase the hyperkalemic activities of Forasartan.
PerindoprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Perindopril.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Forasartan is combined with Pimecrolimus.
PirfenidoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Piroxicam.
PropacetamolThe risk or severity of adverse effects can be increased when Forasartan is combined with Propacetamol.
PTC299The risk or severity of adverse effects can be increased when Forasartan is combined with PTC299.
QuinaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Quinapril.
RamiprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Ramipril.
RescinnamineThe risk or severity of adverse effects can be increased when Forasartan is combined with Rescinnamine.
ResveratrolThe risk or severity of adverse effects can be increased when Forasartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Forasartan.
RofecoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Rofecoxib.
SalicylamideThe risk or severity of adverse effects can be increased when Forasartan is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Forasartan is combined with Salsalate.
SeratrodastThe risk or severity of adverse effects can be increased when Forasartan is combined with Seratrodast.
SpiraprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Spirapril.
SpironolactoneForasartan may increase the hyperkalemic activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Forasartan is combined with SRT501.
SulfasalazineThe risk or severity of adverse effects can be increased when Forasartan is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Forasartan is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Suprofen.
TemocaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Temocapril.
TenoxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Forasartan is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Forasartan is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Tiaprofenic acid.
TinzaparinTinzaparin may increase the hyperkalemic activities of Forasartan.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolmetin.
TolvaptanTolvaptan may increase the hyperkalemic activities of Forasartan.
TrandolaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Trandolapril.
TranilastThe risk or severity of adverse effects can be increased when Forasartan is combined with Tranilast.
TriamtereneForasartan may increase the hyperkalemic activities of Triamterene.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Forasartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Forasartan is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Valdecoxib.
ZaltoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Forasartan is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Forasartan is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Tokunaga R, Kushiku K, Yamada K, Yamada H, Furukawa T: Possible involvement of calcium-calmodulin pathways in the positive chronotropic response to angiotensin II on the canine cardiac sympathetic ganglia. Jpn J Pharmacol. 2001 Aug;86(4):381-9. [PubMed:11569611 ]
  2. Usune S, Furukawa T: Effects of SC-52458, a new nonpeptide angiotensin II receptor antagonist, on increase in cytoplasmic Ca2+ concentrations and contraction induced by angiotensin II and K(+)-depolarization in guinea-pig taenia coli. Gen Pharmacol. 1996 Oct;27(7):1179-85. [PubMed:8981065 ]
  3. Hagmann M, Nussberger J, Naudin RB, Burns TS, Karim A, Waeber B, Brunner HR: SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. J Cardiovasc Pharmacol. 1997 Apr;29(4):444-50. [PubMed:9156352 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:11 / Updated on August 17, 2016 12:23